Uno studio per confrontare Blinatumomab da solo con Blinatumomab con nivolumab in pazienti con diagnosi di prima recidiva di leucemia linfoblastica acuta a cellule B (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Procedura: Bone Marrow Biopsy
- Biologico: Nivolumab
- Biologico: Blinatumomab
- Procedura: Bone Marrow Aspiration
- Procedura: Lumbar Puncture
- Droga: Mercaptopurine
- Droga: Pegaspargase
- Droga: Calaspargase Pegol
- Droga: Dexamethasone
- Droga: Asparaginase Erwinia chrysanthemi
- Droga: Cytarabine
- Procedura: Biospecimen Collection
- Droga: Hydrocortisone Sodium Succinate
- Droga: Methotrexate
- Radiazione: 3-Dimensional Conformal Radiation Therapy
- Droga: Vincristine Sulfate
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To compare event free survival post reinduction (EFS PR) between blinatumomab vs. blinatumomab/nivolumab in Group 4 patients aged ≥ 1 to <31 years old with first relapse of CD19+ B ALL.
II. To compare EFS PR (EFS post-reinduction) between consolidation with blinatumomab vs. blinatumomab/nivolumab in Group 3 patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of blinatumomab/nivolumab in patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
EXPLORATORY OBJECTIVES:
I. In Group 4 patients, compare EFS PR between blinatumomab monotherapy and blinatumomab/nivolumab arms as compared to similar patients treated on the predecessor trial AALL1331.
II. In Group 4 patients, compare toxicity as defined by grade 3 or greater adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab.
III. In Group 4 patients, compare MRD negative second remission (Rem-2) rate after the first cycle of immunotherapy between blinatumomab monotherapy and blinatumomab/nivolumab arms.
IV. In patients with Down syndrome (DS) with first relapse of B-ALL, describe the safety, tolerability and efficacy (as defined by MRD negative second remission, Rem-2) after up to two cycles of blinatumomab/nivolumab.
V. With each Group, perform subset analyses of EFS and overall survival (OS) based on features including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count at first relapse.
OUTLINE:
Patients >= 18 years old with marrow +/- extramedullary (EM) relapse of any duration after initial diagnosis, or patients < 18 years old with marrow +/- EM relapse < 24 months after initial diagnosis are assigned to Group 1. Patients < 18 years old with marrow +/- EM relapse >= 24 months from initial diagnosis, or all isolated extramedullary (IEM) relapses >= 1 to < 31 years old are assigned to Groups 2-3 re-induction. Patients with DS are assigned to Arm G. NOTE: Patients in Group 1 and DS patients with white blood cells (WBC) >= 30,000/uL, CNS 2/3 disease, or testicular disease must first receive 1 of 3 pre-immunotherapy treatments.
Starting with amendment 4C (9/19/2024), patients with DS are assigned to group 3 or 4. Patients < 18 years with bone marrow first relapse ≥ 36 months from initial diagnosis with MRD <0.1% after VXLD reinduction or with isolated CNS/testicular extramedullary relapse occurring ≥ 18 months from initial diagnosis with MRD <0.1% after VXLD reinduction are assigned to group 3. Patients who do not meet criteria for group 3 will be assigned to group 4. Patients with Down syndrome ≥ 1 to < 31 years of age with first bone marrow relapse of B ALL are assigned to arm G.
PRE-IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH WBC >= 30,000/uL (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G) : Patients receive methotrexate (MTX) intrathecally (IT) or cytarabine IT or intrathecal triple therapy (ITT) consisting of MTX, hydrocortisone sodium succinate, and cytarabine IT at the time of diagnostic lumbar puncture (LP) or on day 1 (if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients also receive dexamethasone intravenously (IV) or orally (PO) twice daily (BID) on days 1-5, vincristine sulfate via infusion or IV push over 1 minute on day 1. Patients with DS also receive leucovorin calcium PO or IV every 6 hours (q6h) for 2 doses on day 2 or at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 8 and no later than Day 15.
PRE-IMMUNOTHERAPY TREATMENT FOR CNS 2/3 DISEASE (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT or cytarabine IT twice weekly (Q2W) for 5-7 doses or Intrathecal Triple Therapy (ITT) IT Q2W for 3-4 doses until patient is CNS 1. Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 24.
PRE-IMMUNOTHERAPY TREATMENT FOR TESTICULAR DISEASE(CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT, cytarabine IT, or ITT IT on days 1 and 15 (day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses on days 2 and 16 or at 24 and 30 hours after each IT administration. Males with testicular disease at relapse undergo radiation once daily (QD) for a total of 12 fractions over 12 days. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 22.
GROUP 1 (CLOSED TO ACCRUAL 9/19/2024): Patients are randomized to Arm A or Arm B.
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM B: Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUPS 2-4 VXLD REINDUCTION: Patients receive vincristine sulfate via infusion or IV push over 1 minute on days 1, 8, 15, and 22, dexamethasone PO or IV on days 1-14, doxorubicin hydrochloride IV over 3-15 minutes on day 1, MTX IT on days 1, 8, and 29 (day 1 IT may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of this cycle) (days 8 and 29 for CNS 1 patients at relapse only), pegaspargase intramuscularly (IM) or IV over 1-2 hours on days 2 and 16 or calaspargase IV over 1-2 hours on day 2 (for patients ≤ 22 years), cytarabine IT on days 4 and 11 (CNS 2 patients at relapse only), then Q2W until 3 consecutive samples are clear of blasts, and ITT IT on days 8, 15, 22, and 29 (CNS 3 patients at relapse only). Patients with CNS 2 disease at relapse that does not resolve to CNS 1 by day 15 receive maintenance chemoradiation before initiation of maintenance. Treatment continues in the absence of disease progression or unacceptable toxicity.
GROUP 2 (CLOSED TO ACCRUAL 9/19/2024): The following patients are randomized to Arm C or Arm D: 1) >= 1 to < 31 years old, IEM relapse < 18 months from diagnosis, regardless of MRD after Re-Induction. 2) < 18 years old with marrow relapse >= 24 to < 36 months from diagnosis regardless of MRD after Re-Induction, 3) >= 1 to < 31 years old, IEM relapse >= 18 months, and MRD >= 0.1% after Re-Induction, 4) < 18 years old with marrow relapse >= 36 months, and MRD >= 0.1% after Re-Induction.
ARM C: Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and MTX IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal MTX is given < 7 days prior to the start of cycle 1 ). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM D: Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUP 3: Patients are randomized to Arm E or Arm F.
ARM E:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION: Patients receive dexamethasone PO or IV on days 1-5, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (Omit day 1 for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
ARM F:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and on days 1 of cycles 2 and 3, and MTX IT on days 1 and 15 (CNS 1/2 patients at relapse only)(day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle) or , ITT IT on days 1 and 15 (CNS 3 patients at relapse only) (day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on day 1 and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 (Omit for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
GROUP 4: Patients are randomized to arm H or arm I.
ARM H: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM I: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM G (DS PATIENTS): Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician.
Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
After completion of study treatment, patients are followed up every 3 months for 1 year.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australia, 2310
- Sospeso
- John Hunter Children's Hospital
-
Randwick, New South Wales, Australia, 2031
- Sospeso
- Sydney Children's Hospital
-
Westmead, New South Wales, Australia, 2145
- Sospeso
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Sospeso
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Sospeso
- Perth Children's Hospital
-
-
-
-
-
Québec, Canada, G1V 4G2
- Reclutamento
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Investigatore principale:
- Bruno Michon
-
Contatto:
- Site Public Contact
- Numero di telefono: 418-525-4444
- Email: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Sospeso
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2B7
- Reclutamento
- University of Alberta Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 780-407-8798
- Email: pedsoncologyresearch@ahs.ca
-
Investigatore principale:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Sospeso
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Reclutamento
- CancerCare Manitoba
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-561-1026
- Email: ctu_web@cancercare.mb.ca
-
Investigatore principale:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Reclutamento
- Janeway Child Health Centre
-
Investigatore principale:
- Lisa A. Goodyear
-
Contatto:
- Site Public Contact
- Numero di telefono: 709-777-8727
- Email: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Reclutamento
- IWK Health Centre
-
Contatto:
- Site Public Contact
- Numero di telefono: 902-470-8520
- Email: Research@iwk.nshealth.ca
-
Investigatore principale:
- Chelsea Ash
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Reclutamento
- The Montreal Children's Hospital of the MUHC
-
Contatto:
- Site Public Contact
- Numero di telefono: 514-412-4445
- Email: info@thechildren.com
-
Investigatore principale:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Reclutamento
- Centre Hospitalier Universitaire Sainte-Justine
-
Investigatore principale:
- Monia Marzouki
-
Contatto:
- Site Public Contact
- Numero di telefono: 514-345-4931
- Email: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Reclutamento
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contatto:
- Site Public Contact
- Numero di telefono: 819-820-6480
- Email: crcinformation.chus@ssss.gouv.qc.ca
-
Investigatore principale:
- Stephanie Vairy
-
-
-
-
-
San Juan, Porto Rico, 00926
- Reclutamento
- University Pediatric Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 787-474-0333
-
Investigatore principale:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- Children's Hospital of Alabama
-
Contatto:
- Site Public Contact
- Numero di telefono: 205-638-9285
- Email: oncologyresearch@peds.uab.edu
-
Investigatore principale:
- Matthew A. Kutny
-
Mobile, Alabama, Stati Uniti, 36604
- Reclutamento
- USA Health Strada Patient Care Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-388-8721
-
Investigatore principale:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Reclutamento
- Providence Alaska Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 907-212-6871
- Email: AKPAMC.OncologyResearchSupport@providence.org
-
Investigatore principale:
- Brenda J. Wittman
-
-
Arizona
-
Kingman, Arizona, Stati Uniti, 86401
- Sospeso
- Kingman Regional Medical Center
-
Mesa, Arizona, Stati Uniti, 85202
- Reclutamento
- Banner Children's at Desert
-
Contatto:
- Site Public Contact
- Numero di telefono: 480-412-3100
-
Investigatore principale:
- Joseph C. Torkildson
-
Phoenix, Arizona, Stati Uniti, 85016
- Reclutamento
- Phoenix Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 602-546-0920
-
Investigatore principale:
- Dana B. Salzberg
-
Tucson, Arizona, Stati Uniti, 85719
- Reclutamento
- Banner University Medical Center - Tucson
-
Contatto:
- Site Public Contact
- Email: UACC-IIT@uacc.arizona.edu
-
Investigatore principale:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202-3591
- Reclutamento
- Arkansas Children's Hospital
-
Investigatore principale:
- Michael W. Bishop
-
Contatto:
- Site Public Contact
- Numero di telefono: 501-364-7373
-
-
California
-
Anaheim, California, Stati Uniti, 92806
- Sospeso
- Kaiser Permanente-Anaheim
-
Arroyo Grande, California, Stati Uniti, 93420
- Sospeso
- PCR Oncology
-
Bellflower, California, Stati Uniti, 90706
- Sospeso
- Kaiser Permanente-Bellflower
-
Downey, California, Stati Uniti, 90242
- Reclutamento
- Kaiser Permanente Downey Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 626-564-3455
-
Investigatore principale:
- Robert M. Cooper
-
Duarte, California, Stati Uniti, 91010
- Attivo, non reclutante
- City of Hope Comprehensive Cancer Center
-
Fontana, California, Stati Uniti, 92335
- Reclutamento
- Kaiser Permanente-Fontana
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-398-3996
- Email: clinical.trials@kp.org
-
Investigatore principale:
- Robert M. Cooper
-
Loma Linda, California, Stati Uniti, 92354
- Reclutamento
- Loma Linda University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 909-558-4050
-
Investigatore principale:
- Albert Kheradpour
-
Long Beach, California, Stati Uniti, 90806
- Reclutamento
- Miller Children's and Women's Hospital Long Beach
-
Contatto:
- Site Public Contact
- Numero di telefono: 562-933-5600
-
Investigatore principale:
- Jacqueline N. Casillas
-
Los Angeles, California, Stati Uniti, 90027
- Reclutamento
- Children's Hospital Los Angeles
-
Contatto:
- Site Public Contact
- Numero di telefono: 323-361-4110
-
Investigatore principale:
- Jamie L. Stokke
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Cedars-Sinai Medical Center
-
Investigatore principale:
- Nicole M. Baca
-
Contatto:
- Site Public Contact
- Numero di telefono: 310-423-2133
- Email: Cancer.trial.info@cshs.org
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- Mattel Children's Hospital UCLA
-
Contatto:
- Site Public Contact
- Numero di telefono: 310-825-6708
-
Investigatore principale:
- Satiro N. De Oliveira
-
Los Angeles, California, Stati Uniti, 90027
- Sospeso
- Kaiser Permanente Los Angeles Medical Center
-
Madera, California, Stati Uniti, 93636
- Reclutamento
- Valley Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 559-353-3000
- Email: Research@valleychildrens.org
-
Investigatore principale:
- Ruetima Titapiwatanakun
-
Oakland, California, Stati Uniti, 94611
- Reclutamento
- Kaiser Permanente-Oakland
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-642-4691
- Email: Kpoct@kp.org
-
Investigatore principale:
- Aarati V. Rao
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- Children's Hospital of Orange County
-
Contatto:
- Site Public Contact
- Numero di telefono: 714-509-8646
- Email: oncresearch@choc.org
-
Investigatore principale:
- Elyssa M. Rubin
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Lucile Packard Children's Hospital Stanford University
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-694-0012
- Email: ccto-office@stanford.edu
-
Investigatore principale:
- Jay Michael S. Balagtas
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California Davis Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 916-734-3089
-
Investigatore principale:
- Marcio H. Malogolowkin
-
Sacramento, California, Stati Uniti, 95816
- Reclutamento
- Sutter Medical Center Sacramento
-
Contatto:
- Site Public Contact
- Email: clinicalresearch@sutterhealth.org
-
Investigatore principale:
- Sandra Baril
-
San Diego, California, Stati Uniti, 92120
- Reclutamento
- Kaiser Permanente-San Diego Zion
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-398-3996
- Email: clinical.trials@kp.org
-
Investigatore principale:
- Robert M. Cooper
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- Rady Children's Hospital - San Diego
-
Contatto:
- Site Public Contact
- Numero di telefono: 858-966-5934
-
Investigatore principale:
- William D. Roberts
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- UCSF Medical Center-Mission Bay
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-827-3222
- Email: cancertrials@ucsf.edu
-
Investigatore principale:
- Karen R. Rabin
-
Torrance, California, Stati Uniti, 90502
- Attivo, non reclutante
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- Children's Hospital Colorado
-
Investigatore principale:
- Kelly E. Faulk
-
Contatto:
- Site Public Contact
- Numero di telefono: 303-764-5056
- Email: josh.b.gordon@nsmtp.kp.org
-
Denver, Colorado, Stati Uniti, 80218
- Reclutamento
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 303-832-2344
- Email: PSGResearchSharedMailbox@HCAHealthcare.com
-
Investigatore principale:
- Florence Choo
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Reclutamento
- Connecticut Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 860-545-9981
-
Investigatore principale:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Reclutamento
- Alfred I duPont Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- Children's National Medical Center
-
Investigatore principale:
- Jeffrey S. Dome
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-476-2800
- Email: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, Stati Uniti, 20007
- Reclutamento
- MedStar Georgetown University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-444-2223
-
Investigatore principale:
- Caileigh Pudela
-
-
Florida
-
Fort Myers, Florida, Stati Uniti, 33908
- Reclutamento
- Golisano Children's Hospital of Southwest Florida
-
Contatto:
- Site Public Contact
- Numero di telefono: 239-343-5333
- Email: molly.arnstrom@leehealth.org
-
Investigatore principale:
- Emad K. Salman
-
Gainesville, Florida, Stati Uniti, 32610
- Reclutamento
- UF Health Cancer Institute - Gainesville
-
Investigatore principale:
- Brian Stover
-
Contatto:
- Site Public Contact
- Numero di telefono: 352-273-8010
-
Hollywood, Florida, Stati Uniti, 33021
- Reclutamento
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 954-265-1847
- Email: OHR@mhs.net
-
Investigatore principale:
- Iftikhar Hanif
-
Jacksonville, Florida, Stati Uniti, 32207
- Reclutamento
- Nemours Children's Clinic-Jacksonville
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Emi H. Caywood
-
Orlando, Florida, Stati Uniti, 32806
- Reclutamento
- Arnold Palmer Hospital for Children
-
Investigatore principale:
- Jaime M. Libes-Bander
-
Contatto:
- Site Public Contact
- Numero di telefono: 321-841-5357
- Email: Jennifer.spinelli@orlandohealth.com
-
Orlando, Florida, Stati Uniti, 32827
- Reclutamento
- Nemours Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Investigatore principale:
- Emi H. Caywood
-
Orlando, Florida, Stati Uniti, 32803
- Reclutamento
- AdventHealth Orlando
-
Contatto:
- Site Public Contact
- Numero di telefono: 407-303-2090
- Email: FH.Cancer.Research@flhosp.org
-
Investigatore principale:
- Fouad M. Hajjar
-
Pensacola, Florida, Stati Uniti, 32504
- Sospeso
- Sacred Heart Hospital
-
Pensacola, Florida, Stati Uniti, 32504
- Reclutamento
- Nemours Children's Clinic - Pensacola
-
Contatto:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Investigatore principale:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, Stati Uniti, 33701
- Reclutamento
- Johns Hopkins All Children's Hospital
-
Investigatore principale:
- Jennifer L. Mayer
-
Contatto:
- Site Public Contact
- Numero di telefono: 727-767-4784
- Email: Ashley.Repp@jhmi.edu
-
Tampa, Florida, Stati Uniti, 33606
- Reclutamento
- Tampa General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 813-844-7829
- Email: syapchanyk@tgh.org
-
Investigatore principale:
- Andrew J. Galligan
-
Tampa, Florida, Stati Uniti, 33607
- Reclutamento
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 813-357-0849
- Email: jennifer.manns@baycare.org
-
Investigatore principale:
- Don E. Eslin
-
West Palm Beach, Florida, Stati Uniti, 33407
- Reclutamento
- Saint Mary's Medical Center
-
Investigatore principale:
- Matthew D. Ramirez
-
Contatto:
- Site Public Contact
- Numero di telefono: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Reclutamento
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Investigatore principale:
- Waitman K. Aumann
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-785-0232
- Email: Olivia.Floyd@choa.org
-
Savannah, Georgia, Stati Uniti, 31404
- Reclutamento
- Memorial Health University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 912-350-7887
- Email: Lorraine.OHara@hcahealthcare.com
-
Investigatore principale:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Reclutamento
- Kapiolani Medical Center for Women and Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 808-983-6090
-
Investigatore principale:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Reclutamento
- Saint Luke's Cancer Institute - Boise
-
Investigatore principale:
- Martha M. Pacheco
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Lurie Children's Hospital-Chicago
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-880-4562
-
Investigatore principale:
- Jenna Rossoff
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-702-8222
- Email: cancerclinicaltrials@bsd.uchicago.edu
-
Investigatore principale:
- Gabrielle Lapping-Carr
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- University of Illinois
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-355-3046
-
Investigatore principale:
- Dipti S. Dighe
-
Maywood, Illinois, Stati Uniti, 60153
- Reclutamento
- Loyola University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 708-226-4357
-
Investigatore principale:
- Eugene Suh
-
Peoria, Illinois, Stati Uniti, 61637
- Reclutamento
- OSF Children's Hospital of Illinois
-
Investigatore principale:
- Prerna Kumar
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-624-4945
- Email: ChildrensHospitalofIllinois@osfhealthcare.org
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Riley Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-248-1199
-
Investigatore principale:
- Sandeep Batra
-
Indianapolis, Indiana, Stati Uniti, 46260
- Reclutamento
- Ascension Saint Vincent Indianapolis Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 317-338-2194
- Email: research@stvincent.org
-
Investigatore principale:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Blank Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-8912
- Email: samantha.mallory@unitypoint.org
-
Investigatore principale:
- Samantha L. Mallory
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-237-1225
-
Investigatore principale:
- Andrew P. Groves
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky/Markey Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 859-257-3379
-
Investigatore principale:
- James T. Badgett
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- Norton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-629-5500
- Email: CancerResource@nortonhealthcare.org
-
Investigatore principale:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70118
- Reclutamento
- Children's Hospital New Orleans
-
Investigatore principale:
- Maria C. Velez-Yanguas
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-894-5377
-
New Orleans, Louisiana, Stati Uniti, 70121
- Attivo, non reclutante
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Stati Uniti, 04401
- Reclutamento
- Eastern Maine Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-973-4274
-
Investigatore principale:
- Daniel L. Callaway
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- Maine Children's Cancer Program
-
Investigatore principale:
- Eric C. Larsen
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Investigatore principale:
- Stacy L. Cooper
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Baltimore, Maryland, Stati Uniti, 21215
- Reclutamento
- Sinai Hospital of Baltimore
-
Investigatore principale:
- Jason M. Fixler
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-601-9083
-
Bethesda, Maryland, Stati Uniti, 20889-5600
- Sospeso
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Attivo, non reclutante
- Tufts Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- C S Mott Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-865-1125
-
Investigatore principale:
- Joshua W. Goldman
-
Battle Creek, Michigan, Stati Uniti, 49017
- Sospeso
- Bronson Battle Creek
-
Dearborn, Michigan, Stati Uniti, 48124
- Sospeso
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Stati Uniti, 48201
- Sospeso
- Children's Hospital of Michigan
-
East Lansing, Michigan, Stati Uniti, 48823
- Attivo, non reclutante
- Michigan State University
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Sospeso
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Reclutamento
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Sospeso
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Reclutamento
- Bronson Methodist Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Sospeso
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49048
- Sospeso
- Beacon Kalamazoo
-
Muskegon, Michigan, Stati Uniti, 49444
- Sospeso
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Stati Uniti, 49120
- Sospeso
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Stati Uniti, 49444
- Sospeso
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Stati Uniti, 49677
- Sospeso
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Stati Uniti, 48073
- Reclutamento
- Corewell Health Children's
-
Contatto:
- Site Public Contact
- Numero di telefono: 248-551-7695
-
Investigatore principale:
- Marie V. Nelson
-
Royal Oak, Michigan, Stati Uniti, 48073
- Sospeso
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Sospeso
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Stati Uniti, 49085
- Sospeso
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Stati Uniti, 49684
- Sospeso
- Munson Medical Center
-
Troy, Michigan, Stati Uniti, 48085
- Sospeso
- Corewell Health Beaumont Troy Hospital
-
Wyoming, Michigan, Stati Uniti, 49519
- Sospeso
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55404
- Reclutamento
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Investigatore principale:
- Michael K. Richards
-
Contatto:
- Site Public Contact
- Numero di telefono: 612-813-5913
- Email: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- University of Minnesota/Masonic Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 612-624-2620
-
Investigatore principale:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- Reclutamento
- University of Mississippi Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 601-815-6700
-
Investigatore principale:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- Children's Mercy Hospitals and Clinics
-
Investigatore principale:
- Keith J. August
-
Contatto:
- Site Public Contact
- Numero di telefono: 816-302-6808
- Email: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Kristin Zorn
-
St Louis, Missouri, Stati Uniti, 63141
- Reclutamento
- Mercy Hospital Saint Louis
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-251-7066
-
Investigatore principale:
- Robin D. Hanson
-
St Louis, Missouri, Stati Uniti, 63104
- Reclutamento
- Cardinal Glennon Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-268-4000
-
Investigatore principale:
- William S. Ferguson
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Reclutamento
- Children's Hospital and Medical Center of Omaha
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-955-3949
-
Investigatore principale:
- Jill C. Beck
-
Omaha, Nebraska, Stati Uniti, 68198
- Reclutamento
- University of Nebraska Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Investigatore principale:
- Jill C. Beck
-
-
Nevada
-
Carson City, Nevada, Stati Uniti, 89703
- Sospeso
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Stati Uniti, 89052
- Sospeso
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Stati Uniti, 89052
- Sospeso
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Stati Uniti, 89052
- Sospeso
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Stati Uniti, 89074
- Sospeso
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Las Vegas, Nevada, Stati Uniti, 89135
- Reclutamento
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contatto:
- Site Public Contact
- Numero di telefono: 702-384-0013
- Email: research@sncrf.org
-
Investigatore principale:
- Joseph L. Lasky
-
Las Vegas, Nevada, Stati Uniti, 89144
- Reclutamento
- Summerlin Hospital Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 702-384-0013
- Email: research@sncrf.org
-
Investigatore principale:
- Joseph L. Lasky
-
Las Vegas, Nevada, Stati Uniti, 89103
- Sospeso
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Stati Uniti, 89109
- Sospeso
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89128
- Sospeso
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Stati Uniti, 89128
- Sospeso
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Stati Uniti, 89128
- Sospeso
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Stati Uniti, 89144
- Sospeso
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Stati Uniti, 89144
- Sospeso
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Stati Uniti, 89148-2405
- Sospeso
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Stati Uniti, 89148
- Sospeso
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Stati Uniti, 89169
- Sospeso
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Stati Uniti, 89102
- Sospeso
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stati Uniti, 89183
- Sospeso
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Stati Uniti, 89048
- Sospeso
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Stati Uniti, 89502
- Reclutamento
- Renown Regional Medical Center
-
Investigatore principale:
- Seema L. Rao
-
Contatto:
- Site Public Contact
- Numero di telefono: 775-982-5050
- Email: Renown-CRD@renown.org
-
Reno, Nevada, Stati Uniti, 89503
- Sospeso
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Stati Uniti, 89511
- Sospeso
- Cancer Care Specialists - Reno
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Reclutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Investigatore principale:
- Angela Ricci
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-639-6918
- Email: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- Hackensack University Medical Center
-
Investigatore principale:
- Jing Chen
-
Contatto:
- Site Public Contact
- Numero di telefono: 551-996-2897
-
Morristown, New Jersey, Stati Uniti, 07960
- Reclutamento
- Morristown Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-971-5900
-
Investigatore principale:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-7356
-
Investigatore principale:
- Richard A. Drachtman
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Reclutamento
- Saint Peter's University Hospital
-
Investigatore principale:
- Nibal A. Zaghloul
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-745-8600
- Email: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-8675
-
Investigatore principale:
- Richard A. Drachtman
-
Newark, New Jersey, Stati Uniti, 07112
- Reclutamento
- Newark Beth Israel Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-926-7230
- Email: Christine.Kosmides@rwjbh.org
-
Investigatore principale:
- Teena Bhatla
-
Paterson, New Jersey, Stati Uniti, 07503
- Reclutamento
- Saint Joseph's Regional Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-754-2207
- Email: HallL@sjhmc.org
-
Investigatore principale:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Reclutamento
- Presbyterian Hospital
-
Investigatore principale:
- Beeling Armijo
-
Contatto:
- Site Public Contact
- Numero di telefono: 505-559-6113
- Email: wburman@phs.org
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Albany Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 518-262-5513
-
Investigatore principale:
- Lauren R. Weintraub
-
Brooklyn, New York, Stati Uniti, 11219
- Reclutamento
- Maimonides Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-765-2500
-
Investigatore principale:
- Mahmut Y. Celiker
-
Mineola, New York, Stati Uniti, 11501
- Reclutamento
- NYU Langone Hospital - Long Island
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-263-4432
- Email: cancertrials@nyulangone.org
-
Investigatore principale:
- Chana L. Glasser
-
New Hyde Park, New York, Stati Uniti, 11040
- Reclutamento
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-470-3460
-
Investigatore principale:
- Julie I. Krystal
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Investigatore principale:
- Nobuko Hijiya
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-342-5162
- Email: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-639-7592
-
Investigatore principale:
- Kavitha Ramaswamy
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Investigatore principale:
- Elizabeth A. Raetz
-
Contatto:
- Site Public Contact
- Email: CancerTrials@nyulangone.org
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- NYP/Weill Cornell Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-746-1848
-
Investigatore principale:
- Jaclyn Rosenzweig
-
Rochester, New York, Stati Uniti, 14642
- Attivo, non reclutante
- University of Rochester
-
Stony Brook, New York, Stati Uniti, 11794
- Reclutamento
- Stony Brook University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-862-2215
-
Investigatore principale:
- Laura E. Hogan
-
Syracuse, New York, Stati Uniti, 13210
- Reclutamento
- State University of New York Upstate Medical University
-
Contatto:
- Site Public Contact
- Numero di telefono: 315-464-5476
-
Investigatore principale:
- Melanie A. Comito
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Montefiore Medical Center - Moses Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 718-379-6866
- Email: eskwak@montefiore.org
-
Investigatore principale:
- Alice Lee
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28801
- Reclutamento
- Mission Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 828-213-7055
- Email: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Investigatore principale:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Investigatore principale:
- Thomas B. Alexander
-
Charlotte, North Carolina, Stati Uniti, 28203
- Reclutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-9376
-
Investigatore principale:
- Joel A. Kaplan
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Investigatore principale:
- Jessica M. Sun
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-275-3853
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- East Carolina University
-
Contatto:
- Site Public Contact
- Numero di telefono: 252-744-1015
- Email: eubankss@ecu.edu
-
Investigatore principale:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Wake Forest University Health Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 336-713-6771
-
Investigatore principale:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Investigatore principale:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44308
- Reclutamento
- Children's Hospital Medical Center of Akron
-
Contatto:
- Site Public Contact
- Numero di telefono: 330-543-3193
-
Investigatore principale:
- Lauren R. Draper
-
Cincinnati, Ohio, Stati Uniti, 45229
- Reclutamento
- Cincinnati Children's Hospital Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 513-636-2799
- Email: cancer@cchmc.org
-
Investigatore principale:
- Erin H. Breese
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Rainbow Babies and Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 216-844-5437
-
Investigatore principale:
- Duncan S. Stearns
-
Cleveland, Ohio, Stati Uniti, 44195
- Sospeso
- Cleveland Clinic Foundation
-
Columbus, Ohio, Stati Uniti, 43205
- Reclutamento
- Nationwide Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 614-722-6039
- Email: Melinda.Triplet@nationwidechildrens.org
-
Investigatore principale:
- Mark A. Ranalli
-
Dayton, Ohio, Stati Uniti, 45404
- Reclutamento
- Dayton Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-4055
-
Investigatore principale:
- Jordan M. Wright
-
Sylvania, Ohio, Stati Uniti, 43560
- Sospeso
- ProMedica Flower Hospital
-
Toledo, Ohio, Stati Uniti, 43606
- Reclutamento
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 419-824-1842
- Email: PCIOncResearch@promedica.org
-
Investigatore principale:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Stati Uniti, 74136
- Reclutamento
- Saint Francis Children's Hospital
-
Investigatore principale:
- Jill A. Salo
-
Contatto:
- Site Public Contact
- Numero di telefono: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97227
- Reclutamento
- Legacy Emanuel Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-413-2560
-
Investigatore principale:
- Jason M. Glover
-
Portland, Oregon, Stati Uniti, 97239
- Reclutamento
- Oregon Health and Science University
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-494-1080
- Email: trials@ohsu.edu
-
Investigatore principale:
- Bill H. Chang
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital-Cedar Crest
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-402-9543
- Email: Morgan_M.Horton@lvhn.org
-
Investigatore principale:
- Jacob A. Troutman
-
Danville, Pennsylvania, Stati Uniti, 17822
- Reclutamento
- Geisinger Medical Center
-
Investigatore principale:
- Jagadeesh Ramdas
-
Contatto:
- Site Public Contact
- Numero di telefono: 570-271-5251
- Email: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Reclutamento
- Penn State Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 717-531-6012
-
Investigatore principale:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia
-
Investigatore principale:
- Shannon L. Maude
-
Contatto:
- Site Public Contact
- Numero di telefono: 267-425-5544
- Email: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19134
- Reclutamento
- Saint Christopher's Hospital for Children
-
Contatto:
- Site Public Contact
- Numero di telefono: 215-427-8991
-
Investigatore principale:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- Children's Hospital of Pittsburgh of UPMC
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-692-8570
- Email: jean.tersak@chp.edu
-
Investigatore principale:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Reclutamento
- Rhode Island Hospital
-
Investigatore principale:
- Bradley DeNardo
-
Contatto:
- Site Public Contact
- Numero di telefono: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti, 29203
- Reclutamento
- Prisma Health Richland Hospital
-
Investigatore principale:
- Stuart L. Cramer
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- BI-LO Charities Children's Cancer Center
-
Investigatore principale:
- Aniket Saha
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29615
- Reclutamento
- Prisma Health Cancer Institute - Eastside
-
Investigatore principale:
- Aniket Saha
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
Investigatore principale:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37916
- Reclutamento
- East Tennessee Childrens Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 865-541-8266
-
Investigatore principale:
- Susan E. Spiller
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University/Ingram Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-811-8480
-
Investigatore principale:
- Brianna N. Smith
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- The Children's Hospital at TriStar Centennial
-
Contatto:
- Site Public Contact
- Numero di telefono: 615-342-1919
-
Investigatore principale:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Stati Uniti, 78723
- Reclutamento
- Dell Children's Medical Center of Central Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 512-628-1902
- Email: TXAUS-DL-SFCHemonc.research@ascension.org
-
Investigatore principale:
- Shannon M. Cohn
-
Corpus Christi, Texas, Stati Uniti, 78411
- Reclutamento
- Driscoll Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 361-694-5311
- Email: Crystal.DeLosSantos@dchstx.org
-
Investigatore principale:
- Nkechi I. Mba
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Investigatore principale:
- Tamra L. Slone
-
Dallas, Texas, Stati Uniti, 75230
- Reclutamento
- Medical City Dallas Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 972-566-5588
-
Investigatore principale:
- Maurizio L. Ghisoli
-
El Paso, Texas, Stati Uniti, 79905
- Reclutamento
- El Paso Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 915-298-5444
- Email: ranjan.bista@ttuhsc.edu
-
Investigatore principale:
- Benjamin Carcamo
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Cook Children's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 682-885-2103
- Email: CookChildrensResearch@cookchildrens.org
-
Investigatore principale:
- Kenneth M. Heym
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Investigatore principale:
- Anil George
-
Contatto:
- Site Public Contact
- Numero di telefono: 713-798-1354
- Email: burton@bcm.edu
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- UT MD Anderson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Najat C. Daw
-
Lubbock, Texas, Stati Uniti, 79410
- Reclutamento
- Covenant Children's Hospital
-
Investigatore principale:
- Kishor M. Bhende
-
Contatto:
- Site Public Contact
- Numero di telefono: 806-725-8657
- Email: mbisbee@providence.org
-
Lubbock, Texas, Stati Uniti, 79415
- Reclutamento
- UMC Cancer Center / UMC Health System
-
Contatto:
- Site Public Contact
- Numero di telefono: 806-775-8590
-
Investigatore principale:
- Erin K. Barr
-
San Antonio, Texas, Stati Uniti, 78207
- Reclutamento
- Children's Hospital of San Antonio
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-704-2894
- Email: bridget.medina@christushealth.org
-
Investigatore principale:
- Julie Voeller
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- University of Texas Health Science Center at San Antonio
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-450-3800
- Email: phoresearchoffice@uthscsa.edu
-
Investigatore principale:
- Anne-Marie R. Langevin
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Methodist Children's Hospital of South Texas
-
Contatto:
- Site Public Contact
- Numero di telefono: 210-575-6240
- Email: Vinod.GidvaniDiaz@hcahealthcare.com
-
Investigatore principale:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Reclutamento
- Primary Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 801-585-5270
-
Investigatore principale:
- Luke D. Maese
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05405
- Reclutamento
- University of Vermont and State Agricultural College
-
Contatto:
- Site Public Contact
- Numero di telefono: 802-656-8990
- Email: rpo@uvm.edu
-
Investigatore principale:
- Jessica L. Heath
-
-
Virginia
-
Falls Church, Virginia, Stati Uniti, 22042
- Reclutamento
- Inova Fairfax Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 703-208-6650
- Email: Stephanie.VanBebber@inova.org
-
Investigatore principale:
- Robin Y. Dulman
-
Norfolk, Virginia, Stati Uniti, 23507
- Reclutamento
- Children's Hospital of The King's Daughters
-
Contatto:
- Site Public Contact
- Numero di telefono: 757-668-7243
- Email: CCBDCresearch@chkd.org
-
Investigatore principale:
- Melissa S. Mark
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- VCU Massey Comprehensive Cancer Center
-
Investigatore principale:
- Jordyn R. Griffin
-
Contatto:
- Site Public Contact
- Numero di telefono: 804-628-6430
- Email: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Stati Uniti, 98004
- Sospeso
- Overlake Medical Center
-
Renton, Washington, Stati Uniti, 98055
- Sospeso
- Valley Medical Center
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-987-2000
-
Investigatore principale:
- Sarah E. Leary
-
Spokane, Washington, Stati Uniti, 99204
- Reclutamento
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-228-6618
- Email: HopeBeginsHere@providence.org
-
Investigatore principale:
- Judy L. Felgenhauer
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Mary Bridge Children's Hospital and Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 253-403-1461
- Email: research@multicare.org
-
Investigatore principale:
- Robert G. Irwin
-
Tacoma, Washington, Stati Uniti, 98431
- Reclutamento
- Madigan Army Medical Center
-
Investigatore principale:
- Melissa A. Forouhar
-
Contatto:
- Site Public Contact
- Numero di telefono: 253-968-6144
- Email: melissa.a.forouhar.mil@health.mil
-
Yakima, Washington, Stati Uniti, 98902
- Sospeso
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Bridgeport, West Virginia, Stati Uniti, 26330
- Sospeso
- United Hospital Center
-
Charleston, West Virginia, Stati Uniti, 25304
- Reclutamento
- Vandalia Health/CAMC Institute for Academic Medicine
-
Investigatore principale:
- Mohamad H. Badawi
-
Contatto:
- Site Public Contact
- Numero di telefono: 304-388-9944
- Email: CAMCClinicalTrials@vandaliahealth.org
-
Martinsburg, West Virginia, Stati Uniti, 25401
- Sospeso
- WVUH-Berkely Medical Center
-
Morgantown, West Virginia, Stati Uniti, 26506
- Reclutamento
- West Virginia University Healthcare
-
Contatto:
- Site Public Contact
- Numero di telefono: 304-293-7374
- Email: cancertrialsinfo@hsc.wvu.edu
-
Investigatore principale:
- Ashley E. Meyer
-
Parkersburg, West Virginia, Stati Uniti, 26101
- Sospeso
- Camden Clark Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Stati Uniti, 54301
- Reclutamento
- Saint Vincent Hospital Cancer Center Green Bay
-
Investigatore principale:
- Catherine A. Long
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Madison, Wisconsin, Stati Uniti, 53792
- Reclutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Investigatore principale:
- Cathy A. Lee-Miller
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Children's Hospital of Wisconsin
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-955-4727
- Email: MACCCTO@mcw.edu
-
Investigatore principale:
- Michael J. Burke
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patients must be >= 1 and < 31 years at time of enrollment
-
Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories:
- Isolated bone marrow relapse
- Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
- Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes
-
Patients with Down syndrome (DS) are eligible in the following categories:
- Isolated bone marrow relapse
- Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
-
Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression
-
Patients must not have had a prior hematopoietic stem cell transplant
-
A single intrathecal chemotherapy at the time of relapse will be allowed. If < 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted
-
In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible
- Patients with Down syndrome who received pre-enrollment therapy and have a white blood count (WBC) >= 30,000/ul at the time of enrollment still must receive protocol specified cytoreductive therapy with vincristine and dexamethasone, and no "washout" is required
- Patients with Down syndrome who received pre-enrollment therapy and have a WBC < 30,000/ul at the time of enrollment must be given a 24 hour "washout" before starting immunotherapy
-
Note: There is no waiting period or "washout" for patients who relapse while receiving upfront therapy
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex as follows (within 7 calendar days prior to enrollment):
-
Age: Maximum serum creatinine (mg/dL)
-
1 to < 2 years: 0.6 (male), 0.6 (female)
-
2 to < 6 years: 0.8 (male), 0.8 (female)
-
6 to < 10 years: 1 (male), 1 (female)
-
10 to < 13 years: 1.2 (male), 1.2 (female)
-
13 to < 16 years: 1.5 (male), 1.4 (female)
-
>= 16 years: 1.7 (male), 1.4 (female)
- The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease Control (CDC)
-
-
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by echocardiogram, cardiac magnetic resonance imaging (MRI) or radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Patients with B-lymphoblastic lymphoma (B-LLy)
-
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia
-
Patients with Philadelphia chromosome positive (Ph+) B-ALL or ABL class Ph-like B-ALL (i.e. rearrangements involving ABL1, ABL2, CSF1R or PDGFRB and predicted to be sensitive to imatinib or dasatinib)
-
Patients with mixed phenotype acute leukemia (MPAL)
-
Patients with known Charcot-Marie-Tooth disease
-
Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
-
Patients with active, uncontrolled infection defined as:
- Positive bacterial blood culture within 48 hours of study enrollment
- Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.
- Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for > 48 hours
- A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection
- Active viral or protozoal infection requiring IV treatment
-
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible.
-
Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patients who have been treated and have no viral detectable burden are also eligible
-
Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with CNS involvement
- Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved
-
Patients with an active known/suspected autoimmune disease are not eligible. However, patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
-
Patients with DS patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are not eligible
- Note: Group 3 and 4 patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are eligible if this is NOT the only site of relapsed disease
-
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment. Patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of this study. Men with female partners of childbearing potential should use effective contraception during the duration of their treatment. The effect of blinatumomab on fertility has not been evaluated. Blinatumomab is not recommended for pregnant women or women of childbearing potential (WOCBP) not using contraception. Females of reproductive potential must use effective contraception during treatment and for at least 48 hours after the last dose of blinatumomab. Studies in animal models have shown that nivolumab can adversely impair pregnancy. Thus, nivolumab is expected to cause fetal harm during pregnancy. WOCBP receiving nivolumab must continue contraception for a period of at least 5 months after the last dose of nivolumab. It is unknown whether nivolumab is present in breast milk, thus breastfeeding should be discontinued while a patient is receiving nivolumab
-
Lactating females are not eligible unless they agree to not breastfeed their infants. It is unknown whether blinatumomab or its metabolites are excreted in human breast milk. Women are not permitted to breastfeed while receiving blinatumomab and for the last 48 hours after the last blinatumomab dose. Due to the potential for serious adverse reactions in the breastfed infant, women are not permitted to breastfeed during treatment and for 5 months after the last nivolumab dose
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients
Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
|
Sperimentale: Group 1, Arm A (dexamethasone, blinatumomab, MTX)
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
|
Sperimentale: Group 1, Arm B (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
|
Sperimentale: Group 2, Arm C (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO or IV
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
|
Sperimentale: Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO or IV
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
|
Sperimentale: Group 3, Arm E (dexamethasone, blinatumomab, MTX)
See Outline section |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO
Altri nomi:
Given IM or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or IV
Altri nomi:
Given IM
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
Undergo 3D-CRT
Altri nomi:
Given IV push or via infusion
Altri nomi:
|
|
Sperimentale: Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)
See Outline section |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO
Altri nomi:
Given IM or IV
Altri nomi:
Given IV
Altri nomi:
Given PO or IV
Altri nomi:
Given IM
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
Undergo 3D-CRT
Altri nomi:
Given IV push or via infusion
Altri nomi:
|
|
Sperimentale: Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given IV
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
|
Sperimentale: Group 4, Arm H (dexamethasone blinatumomab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Altri nomi:
Given IV
Altri nomi:
Undergo bone marrow aspiration Undergo lumbar puncture
Altri nomi:
Given PO or IV
Altri nomi:
Given IT
Altri nomi:
Undergo blood, urine and cerebrospinal fluid collection
Altri nomi:
Given IT
Altri nomi:
Given IT, PO, and IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Minimal residual disease (MRD) negative second remission (Rem-2) rate with blinatumomab vs with blinatumomab + nivolumab (Group 1)
Lasso di tempo: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD negative Rem-2 rate between Arm A vs Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.10. Interim analysis will be conducted to monitor for futility. The futility boundaries are based on testing the alternative hypothesis at the 0.067 level. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Event-free survival post-reinduction (EFS PR) (Group 3)
Lasso di tempo: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm E versus Arm F will be based on a one-sided two-sample logrank test with Type I error of 0.15, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
|
EFS PR (Group 4)
Lasso di tempo: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm H versus Arm I will be based on a one-sided two-sample logrank test with Type I error of 0.10, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose-limiting toxicity
Lasso di tempo: Up to 1 cycle of therapy (each cycle = 36 days)
|
Will be assessed using the Common Terminology Criteria for Adverse Events version 5.0. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Lasso di tempo: From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Comparison of EFS post-reinduction between Arm C versus Arm D will be based on a one-sided two-sample logrank test with type I error of 0.15, to be conducted 2 years after completion of enrollment of Group 2. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. |
From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Event-free survival (Group 1)
Lasso di tempo: From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
EFS will be compared between Arm A and Arm B, and to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. |
From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
|
Event free survival (Group 4)
Lasso di tempo: From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
EFS of Arm H and Arm I will be compared to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
|
Incidence of adverse events in Arm A or Arm B
Lasso di tempo: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events in Arm H or Arm I
Lasso di tempo: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Group 2)
Lasso di tempo: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 rate will be estimated and be compared between Arm C and Arm D using two-sample test of proportions. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Dose-limiting toxicity (Down syndrome patients)
Lasso di tempo: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events (Down syndrome patients)
Lasso di tempo: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Down syndrome patients)
Lasso di tempo: Up to 2 cycles of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of EFS
Lasso di tempo: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of OS
Lasso di tempo: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Lasso di tempo: At 2 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm H and I. |
At 2 years from date of randomization
|
|
EFS PR (Group 3)
Lasso di tempo: At 3 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm E and F. |
At 3 years from date of randomization
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Stacy L Cooper, Children's Oncology Group
Pubblicazioni e link utili
Pubblicazioni generali
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del sistema nervoso
- Neoplasie
- Malattie genetiche, congenite
- Malattie del sistema immunitario
- Infezioni
- Malattie virali
- Neoplasie per tipo istologico
- Manifestazioni neurocomportamentali
- Infezioni da virus del DNA
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Anomalie congenite
- Linfoma, cellule B
- Linfoma
- Anomalie multiple
- Disabilità intellettuale
- Infezioni da virus di Epstein-Barr
- Infezioni da Herpesviridae
- Infezioni da virus tumorali
- Disturbi cromosomici
- Malattie e anomalie congenite, ereditarie e neonatali
- Malattie emiche e linfatiche
- Linfoma di Burkitt
- Sindrome di Down
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Forature
- Procedure chirurgiche, operative
- Tecniche citologiche
- Acidi nucleici, nucleotidi e nucleosidi
- Citodiagnosi
- Idrocarburi
- Idrocarburi, ciclici
- Alcaloidi
- Idrocarburi, aromatici
- Composti policiclici
- Idrolasi
- Enzimi
- Enzimi e coenzimi
- Indoli
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Purine
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Derivati di benzene
- Tecniche diagnostiche, chirurgiche
- Acidi solfonici
- Acidi zolfo
- Nucleosidi
- Pterins
- Pteridine
- Incintadienetrioli
- Amidoidrolasi
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Arabinonucleosidi
- Aminopterino
- Radioterapia
- Gravideniones
- Incinta
- 11-idrossicosteroidi
- Idrossicorticosteroidi
- Ormoni della corteccia surrenale
- 17-idrossicosteroidi
- Tecniche diagnostiche, neurologiche
- Benzenesolfonati
- Arilsulfonati
- Acidi arilsolfonici
- Radioterapia, assistita da computer
- Composti solfidrilici
- Nivolumab
- Desametasone
- Metotrexato
- Citarabina
- Vincristina
- Idrocortisone
- Asparaginasi
- Mercaptopurina
- Dobesilato di calcio
- Biopsia
- Gestione dei campioni
- Blinatumomab
- Puntura spinale
- desametasone 21-fosfato
- N, N-DICHCLOHEXYL-ISOBORNEOL-10-Sulfonamide
- Calaspargase Pegol
- azathiopurina
- Merphos
- pegaspargase
- Radioterapia, conforme
- auricolare
- desametasone acetato
- asparaginasi Erwinia chrysanthemi ricombinante
- emisuccinato di idrocortisone
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2020-06813
- U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2020-06813 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- AALL1821 (Altro identificatore: CTEP)
- AALL1821 (Altro identificatore: Children's Oncology Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .